Id: acc0005
Group: 1sens
Protein: PTEN
Gene Symbol: PTEN
Protein Id: P60484
Protein Name: PTEN_HUMAN
PTM: acetylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Hepatocellular Carcinoma
Disease Subtype:
Disease Cellline: SMMC-7721
Disease Info:
Drug: pterostilbene
Drug Info: "Pterostilbene is a naturally occurring stilbenoid compound with potent antioxidant, anti-inflammatory, and potential anticancer properties, also recognized for its role in inhibiting melanogenesis by targeting tyrosinase activity and endothelin antagonism in cosmetic or pharmaceutical applications."
Effect: modulate
Effect Info: "Rosewood inhibits the MTA1/HDAC1 complex, leading to PTEN acetylation in hepatocellular carcinoma."
Note:
Score: 4.0
Pubmed(PMID): 29635894
Sentence Index:
Sentence:

Sequence & Structure:

MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - D Glioblastoma Methylation 3747204
- - D Non-small cell lung cancer Ubiquitination 31001918
- - D Hepatocellular carcinoma Ubiquitination 30056112
- - D Prostate cancer Ubiquitination 33155366
- - D Pancreatic cancer Ubiquitination 34743406
- - D Non-small cell lung cancer Ubiquitination 34533198
- - D Non-small cell lung cancer Ubiquitination 34416231
- - D Non-small cell lung cancer Ubiquitination 31197957
- - D Lung cancer Ubiquitination 28852924
- - D Osteoarthritis Ubiquitination 33378983
- - D Glioblastoma Methylation 23977117
- - P Acute myeloid leukemia/acute myelogenous leukemia Phosphorylation 15297415
- - U Colorectal cancer Ubiquitination 31296997
- - U Glioblastoma Ubiquitination 32737433
- - U Cancer Ubiquitination 25547115
- - U Hepatocellular carcinoma Ubiquitination 29958993
- - U Hepatocellular carcinoma Ubiquitination 37098835
- - U Non-small cell lung cancer Ubiquitination 35499228
- - U Ovarian cancer Ubiquitination 35174471
- - U T-cell acute lymphocytic leukemia Ubiquitination 36923153
- - U Non-small cell lung cancer Ubiquitination 35765958
- - U Non-small cell lung cancer Ubiquitination 34416231
- - U Bladder cancer Ubiquitination 33664240
- - U Esophagus cancer Ubiquitination 31719796
- - U Prostate cancer Ubiquitination 37715829
- - U Fibromyomatous uteri Phosphorylation 17097286
- - U Lymphocytic leukemia Phosphorylation 24278390
- - U Chronic lymphocytic leukemia Phosphorylation 20660292
- - U Hepatocellular carcinoma Phosphorylation 35864529
- - U Breast cancer Neddylation 38167440
- - U Ovarian cancer/carcinoma Methylation 23933187

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: